ライフサイエンスコーパス: osteoarthritis

1 beta inhibition for treatment of large joint osteoarthritis.

2 ue, bone marrow and preradiographic signs of osteoarthritis.

3 t for delivering exercise therapies for knee osteoarthritis.

4 -based drug currently in clinical trials for osteoarthritis.

5 joint development and in the pathogenesis of osteoarthritis.

6 chondrocyte protein translation capacity in osteoarthritis.

7 lso in drug testing and disease modeling for osteoarthritis.

8 lation changes in cartilage diseases such as osteoarthritis.

9 evelopment, homeostasis and breakdown during osteoarthritis.

10 thways relevant to cartilage homeostasis and osteoarthritis.

11 ions could be a therapeutic option for human osteoarthritis.

12 ative changes in the knee joint that lead to osteoarthritis.

13 ling axis is critical for the development of osteoarthritis.

14 tening and represents the hallmark change of osteoarthritis.

15 loss due to disuse atrophy and those due to osteoarthritis.

16 ng is deeply involved in the pathogenesis of osteoarthritis.

17 narrowing progression in patients with nodal osteoarthritis.

18 iabetes, cancer, cardiovascular disease, and osteoarthritis.

19 n femoral head affected by a disease such as osteoarthritis.

20 nt option planning to prevent post-traumatic osteoarthritis.

21 erexpression alleviated hMSC aging and mouse osteoarthritis.

22 eumatoid arthritis, also type-2 diabetes and osteoarthritis.

23 tment of cartilage-related diseases, such as osteoarthritis.

24 ith a known role in chondrocyte function and osteoarthritis.

25 hip replacement constructs in patients with osteoarthritis.

26 s of recommended treatments for non-surgical osteoarthritis.

27 the bone, including rheumatoid arthritis and osteoarthritis.

28 with late-stage isolated medial compartment osteoarthritis.

29 s could provide therapeutic benefit in human osteoarthritis.

30 nditions, including hypertension, cancer and osteoarthritis.

31 lity as a therapy for joint pathologies like osteoarthritis.

32 consideration of his widespread age-related osteoarthritis.

33 ion supportive of evaluation for efficacy in osteoarthritis.

34 tential target for gene therapy to alleviate osteoarthritis.

35 tis, knee and/or hip osteoarthritis, and any osteoarthritis.

36 arious aging-associated disorders, including osteoarthritis.

37 ed for covariates) but not with radiographic osteoarthritis.

38 537 outpatients with symptomatic hip or knee osteoarthritis.

39 levels and inhibit cartilage degradation in osteoarthritis.

40 in adolescents and is a major cause of early osteoarthritis.

41 ing that can slow or stop the progression of osteoarthritis.

42 ction and could contribute to the process of osteoarthritis.

43 showing how it impacts mouse knee-shape and osteoarthritis.

44 actions and are associated with the onset of osteoarthritis.

45 restricted to participants with a history of osteoarthritis.

46 of zoledronic acid in the treatment of knee osteoarthritis.

47 reliably assess radiographic features of hip osteoarthritis.

48 accelerated progression of aging-associated osteoarthritis.

49 models of spontaneous and surgically induced osteoarthritis.

50 mice predisposes to the development of knee osteoarthritis.

51 be a new therapeutic target for treating TMJ osteoarthritis.

52 the degenerative effects in a mouse model of osteoarthritis.

53 erlap with differentially methylated CpGs in osteoarthritis.

54 f joints and to the onset and progression of osteoarthritis.

55 nderwent elective surgery due to severe knee osteoarthritis.

56 rtilage, and in cartilage from patients with osteoarthritis.

57 ofacial complex and is subject to injury and osteoarthritis.

58 therapies for skeletal pathologies, such as osteoarthritis.

59 lung fibrosis, atherosclerosis, diabetes and osteoarthritis(1,7).

60 ment in four core recommended treatments for osteoarthritis, (2) describe the barriers and motivators

61 a possible contributor to the development of osteoarthritis(5-7).

62 erformed a genome-wide association study for osteoarthritis (77,052 cases and 378,169 controls), anal

63 85.0 billion [95% CI, $80.5-$90.2 billion]), osteoarthritis ($80.0 billion [95% CI, $72.2-$86.1 billi

64 alth and to treat or slow the progression of osteoarthritis, a debilitating joint disease causing car

65 and asthma, in turn distinguishing them from osteoarthritis, a primarily degenerative disease.

66 Osteoarthritis affects the morphological properties of t

67 are the mainstay of treatment for end-stage osteoarthritis and are effective.

68 nality and pain of patients with hip or knee osteoarthritis and arthroplasty and analyze the associat

69 Among patients with symptomatic knee osteoarthritis and bone marrow lesions, yearly zoledroni

70 f analgesia in chronic pain states including osteoarthritis and chronic low back pain.

71 ighly relevant to cardiovascular disease and osteoarthritis and during development.

72 tegies for FGF signalling-based treatment of osteoarthritis and for cartilage repair in animal models

73 expression changes in cartilage ageing, and osteoarthritis and in osteoarthritis-like conditions, an

74 85 years with symptomatic, radiographic knee osteoarthritis and Kellgren-Lawrence grade 2 or 3.

75 Patients with symptoms of early osteoarthritis and Kellgren-Lawrence grade I-II on plain

76 h by estimating the association between knee osteoarthritis and mortality.

77 and monitoring treatment for cancer, stroke, osteoarthritis and oedema.

78 ar-weight-hyaluronan (HMWH) is used to treat osteoarthritis and other pain syndromes.

79 arathyroidism, osteomalacia, enthesopathies, osteoarthritis and pseudofractures in adults.

80 Dogs, which develop spontaneous osteoarthritis and represent an increasingly used model

81 aged 50 years or older with symptomatic knee osteoarthritis and subchondral bone marrow lesions detec

82 studies in a murine model of post-traumatic osteoarthritis and suggest that the ability of peptide-s

83 mendations for the management of symptomatic osteoarthritis and what factors limit or motivate engage

84 Americans (>=50 years of age) with clinical osteoarthritis and/or provider-diagnosed osteoarthritis

85 thritis, hip osteoarthritis, knee and/or hip osteoarthritis, and any osteoarthritis.

86 , FGFR1 and FGFR3 are strongly implicated in osteoarthritis, and FGFR1 antagonists, as well as agonis

87 up disease as a product of his advanced age, osteoarthritis, and lordosis.

88 their functional significance in ageing and osteoarthritis, and provides potential diagnostic biomar

89 (PPP), joint hyperextensibility, early onset osteoarthritis, ankylosing spondylitis, and seronegative

90 e mechanisms involved in rapidly progressive osteoarthritis are also discussed and future studies pro

91 December 2017 in one of 461 hospitals, with osteoarthritis as the only indication.

92 o, Canada, who had undergone primary THA for osteoarthritis between April 1, 2015, and March 31, 2018

93 studies have implicated at least 35 loci in osteoarthritis but, due to linkage disequilibrium, the s

94 their protein translational capacity during osteoarthritis, but a study of how disease-relevant sign

95 e of bone marrow lesions in people with knee osteoarthritis, but data from large trials are lacking.

96 cal function in people with symptomatic knee osteoarthritis, but the benefits of this therapy are unc

97 biphasic role in adult cartilage health and osteoarthritis by maintaining homeostasis and contributi

98 Late-stage isolated medial knee osteoarthritis can be treated with total knee replacemen

99 Human osteoarthritis cartilage contains chondrocytes (OAC) and

100 mmature, mature and trypsinased (as model of osteoarthritis) cartilage samples to determine the dynam

101 e we demonstrate implications of a snoRNA in osteoarthritis chondrocyte biology and investigated its

102 Conventional inclusion criteria used in osteoarthritis clinical trials are not very effective in

103 e-specific deletion of Gremlin-1 decelerates osteoarthritis development, while intra-articular admini

104 r differential misclassification of the knee osteoarthritis diagnosis and confounding from unmeasured

105 Notably, bone from patients with osteoarthritis displays similar defective nuclear mechan

106 s under investigation as a disease-modifying osteoarthritis drug.

107 it further evaluation as a disease-modifying osteoarthritis drug.

108 o deliver exercise-related services for knee osteoarthritis efficiently and according to patient need

109 ch Multiple Endpoint Vitamin D Trial in Knee Osteoarthritis enrolled adults aged >=60 y who underwent

110 hysical activity, symptoms, and radiographic osteoarthritis features (Kellgren and Lawrence [KL] grad

111 learning model for grading radiographic hip osteoarthritis features on radiographs and compare its p

112 sent in all genotypes and the development of osteoarthritis features was not found accelerated in pre

113 5 single nucleotide variants associated with osteoarthritis for regulatory activity using a massively

114 In humans, pain due to osteoarthritis has been demonstrated to be associated wi

115 ies in individuals with painful knee and hip osteoarthritis have revealed that NGF inhibitors substan

116 9 controls), analyzing four phenotypes: knee osteoarthritis, hip osteoarthritis, knee and/or hip oste

117 Knowledge and research results about hand osteoarthritis (hOA) are limited due to the lack of samp

118 The development of hand osteoarthritis (HOA) could be linked to hyperlipidaemia.

119 in humans and horses and in human late-stage osteoarthritis; however, it is unknown how synovial lubr

120 so increased the risk of rapidly progressive osteoarthritis in a small percentage of those treated.

121 enchymal stem cells (hMSCs) and ameliorating osteoarthritis in mice.

122 monstrate that lack of mast cells attenuates osteoarthritis in mice.

123 g YAP or FOXD1 attenuated the development of osteoarthritis in mice.

124 Patients with osteoarthritis in one or both knees were randomly assign

125 e nanoparticles prevented the development of osteoarthritis in this model.

126 To simulate osteoarthritis in vitro, human articular cartilage expla

127 to ageing (including SNORD96A, SNORD44) and osteoarthritis (including SNORD26 and SNORD116).

128 Eight DXA area loci associate with osteoarthritis, including rs143384 in GDF5 and a missens

129 he Western Ontario and McMaster Universities Osteoarthritis Index (-37.5 vs -58.0, respectively; betw

130 he Western Ontario and McMaster Universities Osteoarthritis Index (0 [no pain] to 500 [unbearable pai

131 he Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 1 year (scores range fro

132 n Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) Pain (0-10, no to extreme p

133 he Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscore standardized

134 as Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.

135 al Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores.

136 al Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score, pain score, st

137 amine the efficacy of IL-1beta inhibitors in osteoarthritis, information on structural joint outcomes

138 in OA patients enrolled in the longitudinal Osteoarthritis Initiative (OAI) study.

139 In the Osteoarthritis Initiative (OAI), a prospective cohort wi

140 pelvic radiographs from participants in the Osteoarthritis Initiative (OAI).

141 Radiographs from the Osteoarthritis Initiative staged by a radiologist commit

142 argest and best characterised OA cohort (NIH Osteoarthritis Initiative).

143 x healthy individuals were selected from the Osteoarthritis Initiative, with no symptoms or visual si

144 isit of individuals who were enrolled in the Osteoarthritis Initiative.

145 ted in vivo in a rat model of post-traumatic osteoarthritis; intra-articular injection of adenosine n

146 Osteoarthritis is a chronic disease characterized by the

147 Osteoarthritis is a common degenerative joint disease fo

148 Osteoarthritis is a common inflammatory disorder with no

149 Osteoarthritis is a long-term condition, and four core t

150 Osteoarthritis is an increasingly important health probl

151 Osteoarthritis is characterized by articular cartilage b

152 A key feature of osteoarthritis is the gradual loss of articular cartilag

153 Osteoarthritis is the most common musculoskeletal diseas

154 he mechanical environment and destruction in osteoarthritis is the pathophysiological consequence of

155 ) can reduce the consequences of large joint osteoarthritis is unclear.

156 is in osteoarthritis, ribosome biogenesis in osteoarthritis is unexplored.

157 iated with reduced risk of radiographic knee osteoarthritis joint space narrowing progression in pati

158 ng four phenotypes: knee osteoarthritis, hip osteoarthritis, knee and/or hip osteoarthritis, and any

159 and nutrients have been associated with knee osteoarthritis (KOA) progression, the association betwee

160 In vitro experiments using osteoarthritis-like conditions affected snoRNA expressio

161 Changes in snoRNAs in osteoarthritis-like conditions were studied in chondrocy

162 cartilage ageing, and osteoarthritis and in osteoarthritis-like conditions, and when the expression

163 g IL-1beta (a classic pathogenic cytokine in osteoarthritis), mainly inflammatory macrophages and den

164 uppressing hypertrophy and MMP-13 in a mouse osteoarthritis model.

165 effects on bone and cartilage in preclinical osteoarthritis models.

166 Osteoarthritis (OA) affects nearly 10% of the population

167 Osteoarthritis (OA) and intervertebral disc degeneration

168 Pain is the major symptom of osteoarthritis (OA) and is an important factor in strate

169 to the nature of lupus arthritis (LA), using osteoarthritis (OA) and rheumatoid arthritis (RA) as com

170 nd monitoring of individuals with early knee osteoarthritis (OA) are important considerations for the

171 multiple sclerosis (MS), arthritis (RA), and osteoarthritis (OA) both in humans and in animal models,

172 The development of osteoarthritis (OA) correlates with a rise in the number

173 The diagnosis of osteoarthritis (OA) currently depends on the presence of

174 gical lubricant implicated to be involved in osteoarthritis (OA) development.

175 Background The methods for assessing knee osteoarthritis (OA) do not provide enough comprehensive

176 prevented clinical translation of promising osteoarthritis (OA) drugs.

177 Osteoarthritis (OA) has been recognized as the most comm

178 Research into the molecular genetics of osteoarthritis (OA) has been substantially bolstered in

179 and their involvement in the pathogenesis of osteoarthritis (OA) have been extensively researched.

180 treatment options for the management of knee osteoarthritis (OA) have been limited to analgesics, glu

181 Chronic disability in TMJ osteoarthritis (OA) increases with aging, and the main g

182 Hip osteoarthritis (OA) is a common cause of pain and disabi

183 Osteoarthritis (OA) is a common cause of pain and disabi

184 Osteoarthritis (OA) is a common degenerative joint disea

185 Knee Osteoarthritis (OA) is a common musculoskeletal disorder

186 Osteoarthritis (OA) is a common, painful disease.

187 Osteoarthritis (OA) is a complex musculoskeletal disease

188 Osteoarthritis (OA) is a degenerative condition caused b

189 Temporomandibular joint (TMJ) osteoarthritis (OA) is a degenerative disease of the joi

190 Osteoarthritis (OA) is a degenerative disease resulting

191 Osteoarthritis (OA) is a degenerative joint disease, and

192 Osteoarthritis (OA) is a disease characterized by cartil

193 Osteoarthritis (OA) is a global disease that, despite ex

194 Knee osteoarthritis (OA) is a heterogeneous disease associate

195 Osteoarthritis (OA) is a highly prevalent chronic condit

196 Knee osteoarthritis (OA) is a leading cause of chronic disabi

197 Osteoarthritis (OA) is an age-associated disease charact

198 Osteoarthritis (OA) is characterized by cartilage destru

199 Osteoarthritis (OA) is characterized by macrophage-drive

200 e relationship between Osteoporotic (OP) and osteoarthritis (OA) is complex.

201 Today, osteoarthritis (OA) is detected after bone damage has oc

202 Radiographic osteoarthritis (OA) is most prevalent in the hand.

203 Current management of osteoarthritis (OA) is primarily focused on symptom cont

204 Osteoarthritis (OA) is the most common arthritis and its

205 Osteoarthritis (OA) is the most common chronic degenerat

206 Osteoarthritis (OA) is the most common degenerative join

207 An emerging therapeutic strategy for osteoarthritis (OA) is to selectively eliminate senescen

208 of inflammation to the chronic joint disease osteoarthritis (OA) is unclear, and this lack of clarity

209 Patients with osteoarthritis (OA) may remain symptomatic with traditio

210 Osteoarthritis (OA) of the hip and knee is among the mos

211 results of a meta-analysis of the impact of osteoarthritis (OA) on cognitive decline and overall mor

212 Clinically, osteoarthritis (OA) pain is significantly associated wit

213 fragmentation is enhanced in chondrocytes of osteoarthritis (OA) patients.

214 nd The exact contribution of statins to knee osteoarthritis (OA) radiographic outcomes and the charac

215 are the most direct route for administering osteoarthritis (OA) therapies, yet how drug carriers dis

216 d arthritis (RA), psoriatic arthritis (PsA), osteoarthritis (OA)) or chronic inflammatory conditions

217 ality of care for patients with hip and knee osteoarthritis (OA), a structured model for integrated O

218 ynovial inflammation is a central feature of osteoarthritis (OA), elicited when local regulatory macr

219 The hallmark of joint diseases, such as osteoarthritis (OA), is pain, originating from both infl

220 M from those with rheumatoid arthritis (RA), osteoarthritis (OA), or systemic lupus erythematosus (SL

221 Osteoarthritis (OA), the most common joint disorder, is

222 in subchondral bone in murine models of knee osteoarthritis (OA), three key parameters, subchondral b

223 These processes contribute to osteoarthritis (OA), where chondrocytes experience a phe

224 Hip shape is an important determinant of hip osteoarthritis (OA), which occurs more commonly in women

225 degradation has been observed in idiopathic osteoarthritis (OA), while the detailed mechanism still

226 high-fat diet (HFD) become obese and develop osteoarthritis (OA)-like lesions, including chondrocyte

227 nce and cartilage degeneration, resulting in osteoarthritis (OA).

228 shment and progression of obesity-associated osteoarthritis (OA).

229 ggravated spontaneous and surgically induced osteoarthritis (OA).

230 , and the development of pathologies such as osteoarthritis (OA).

231 of synovial tissue from patients with RA or osteoarthritis (OA).

232 ) offer a promising therapeutic approach for osteoarthritis (OA).

233 s closely related to the progression of knee osteoarthritis (OA).

234 Inflammation plays a critical role in osteoarthritis (OA).

235 tion Factor 5 (GDF5) is a key risk locus for osteoarthritis (OA).

236 ellular regenerative medicine approaches for osteoarthritis (OA).

237 s mellitus (DM) and knee pain in people with osteoarthritis (OA).

238 asia of the hip (DDH) often show early-onset osteoarthritis (OA); however, the molecular mechanisms u

239 Today, osteoarthritis occurs in 250 million people, with risk v

240 Total joint replacements for end-stage osteoarthritis of the hip and knee are cost-effective an

241 bly age and sex matched) without symptoms of osteoarthritis of the knee were drawn from patient's rel

242 Patients with osteoarthritis of the knee who underwent physical therap

243 artilage and meniscal matrix degeneration in osteoarthritis of the knee, and help in initiating treat

244 rsus PKR in patients with medial compartment osteoarthritis of the knee, and this represents an analy

245 therapy versus glucocorticoid injection for osteoarthritis of the knee.

246 n to confer clinical benefit with respect to osteoarthritis of the knee.

247 ed approach, in which patients with isolated osteoarthritis of the medial compartment of the knee and

248 Osteoporotic osteoarthritis (OPOA) is a common bone disease mostly in

249 Participants were recruited from the osteoarthritis outpatient clinic at Copenhagen Universit

250 In order to maximize the benefits of osteoarthritis pain self-management, older Black America

251 ghlights a role of HBP1 and Wnt signaling in osteoarthritis pathogenesis.

252 Thus, we expect to boost future studies into osteoarthritis patient-specific therapeutic intervention

253 of articular cartilage and menisci in early osteoarthritis patients and healthy volunteers.

254 age and menisci were significantly higher in osteoarthritis patients as compared to healthy volunteer

255 between normal healthy volunteers and early osteoarthritis patients.

256 cell line, and in chondrocytes derived from osteoarthritis patients.

257 ifficulty), and patient global assessment of osteoarthritis (PGA-OA) (1-5, very good to very poor) sc

258 Osteoarthritis presents as a change in the chondrocyte p

259 been reported in experimental post-traumatic osteoarthritis (PTOA) animal models and in naturally occ

260 Post-traumatic osteoarthritis (PTOA) is associated with cartilage degra

261 egradation and progression of post traumatic osteoarthritis (PTOA).

262 utcome was patient-reported quality of care (OsteoArthritis Quality Indicator questionnaire; 0-100, 1

263 , SETTING, AND PARTICIPANTS: FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of R

264 nges in chondrogenic, hypertrophic, rRNA and osteoarthritis related gene expression.

265 t THR/TKR and time to first occurrence of an osteoarthritis-related adverse event (AE).

266 The HR for the secondary end point of osteoarthritis-related AEs was 0.73 (CI, 0.61 to 0.87).

267 , mild, moderate, or severe according to the Osteoarthritis Research Society International atlas.

268 aphic JSN progression was evaluated by using Osteoarthritis Research Society International grading (p

269 ge destruction and a correspondingly reduced Osteoarthritis Research Society International score at 4

270 ups, articular cartilage was degenerated and Osteoarthritis Research Society International score was

271 ribed to regulate chondrocyte homeostasis in osteoarthritis, ribosome biogenesis in osteoarthritis is

272 r Th cell suppressive capacity compared with osteoarthritis SF.

273 es wherein detailed structural assessment of osteoarthritis still relies on expert radiologists' read

274 Using data from two long-term knee osteoarthritis studies OAI and CHECK, we tested multiple

275 We used data from the Malmo Osteoarthritis Study (MOA), a small cohort study from Sk

276 mast cell activation in the pathogenesis of osteoarthritis, suggesting that targeting mast cells cou

277 Mechanical loading mitigates osteoarthritis symptoms by regulating endoplasmic reticu

278 TEP-KOA reported modest improvements in knee osteoarthritis symptoms compared with the control group.

279 predicted risk of total knee replacement in osteoarthritis than did binary outcome models by using s

280 al WOMAC score in patients with hip and knee osteoarthritis, the absolute MCID is 7 U (95% CI, 4 to 1

281 ticipants with symptomatic radiographic knee osteoarthritis, the intra-articular administration of 10

282 cross-talk between cartilage and synovium in osteoarthritis, the most widespread arthritis in the wor

283 ue regeneration holds promise for a feasible osteoarthritis therapeutic application.

284 For osteoarthritis there was increased relative risk associa

285 r mechanisms underlying cartilage ageing and osteoarthritis through the dysregulation of snoRNAs.

286 g, and human rare-disease, animal-model, and osteoarthritis tissue expression data.

287 Temporomandibular joint osteoarthritis (TMJ OA) leads to permanent cartilage des

288 linical pathology of temporomandibular joint osteoarthritis (TMJ-OA) and is promoted through dysfunct

289 dibular joint (TMJ) disorders, including TMJ osteoarthritis (TMJ-OA).

290 ndylar morphology in temporomandibular joint osteoarthritis (TMJOA).

291 Among participants with knee pain from osteoarthritis, use of biomechanical footwear compared w

292 que-that can be applied in the assessment of osteoarthritis using a new quantitative 3D analysis tech

293 region in 2008 and assessed whether they had osteoarthritis using data from the Skane Healthcare Regi

294 knee regulatory elements, which also overlap osteoarthritis variants that contribute to disease herit

295 cal osteoarthritis and/or provider-diagnosed osteoarthritis were enrolled.

296 patellofemoral replacements in patients with osteoarthritis were included.

297 h symptomatic, radiologically confirmed knee osteoarthritis were recruited between April 20, 2015, an

298 The adjusted association of knee osteoarthritis with all-cause mortality in the MOA sampl

299 present an increasingly used model for human osteoarthritis, would be expected to show similar sleep

300 d in several age-related disorders including osteoarthritis, yet its relative contribution to pathoge